CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. - Wikidata - awgldk - TriplyDB

CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody.

CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody.

http://www.wikidata.org/entity/Q33677456

about

Natural killer cell mediated antibody-dependent cellular cytotoxicity in tumor immunotherapy with therapeutic antibodies Novel agents for chronic lymphocytic leukemia Anti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma Therapy New strategies in chronic lymphocytic leukemia: shifting treatment paradigms CD19 as an attractive target for antibody-based therapy Advances in Therapeutic Fc Engineering - Modulation of IgG-Associated Effector Functions and Serum Half-life CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis Dexamethasone-(C21-phosphoramide)-[anti-EGFR]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency against pulmonary adenocarcinoma (A549)Antibody Therapies in Cancer.Update on chronic lymphocytic leukemia: overview of new agents and comparative analysis.A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art.Dose escalation of lenalidomide in relapsed or refractory acute leukemias.Macrophage and NK-mediated killing of precursor-B acute lymphoblastic leukemia cells targeted with a-fucosylated anti-CD19 humanized antibodies Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma.Cloning and Expression of CD19, a Human B-Cell Marker in NIH-3T3 Cell Line.Targeted treatment for chronic lymphocytic leukemia.Initial testing of lenalidomide by the pediatric preclinical testing program Macrophages are critical effectors of antibody therapies for cancer Fludarabine- (C2-methylhydroxyphosphoramide)- [anti-IGF-1R]: Synthesis and Selectively "Targeted"Anti-Neoplastic Cytotoxicity against Pulmonary Adenocarcinoma (A549)Development of an antibody that neutralizes soluble IgE and eliminates IgE expressing B cells.Single-agent MOR208 salvage and maintenance therapy in a patient with refractory/relapsing diffuse large B-cell lymphoma: a case report.XmAb-5574 antibody demonstrates superior antibody-dependent cellular cytotoxicity as compared with CD52- and CD20-targeted antibodies in adult acute lymphoblastic leukemia cells.The potential of immunomodulatory drugs in the treatment of solid tumors.Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia.Therapeutic targeting of CD19 in hematological malignancies: past, present, future and beyond.Signaling mechanisms regulating B-lymphocyte activation and tolerance.Promising therapies for the treatment of chronic lymphocytic leukemia.Emerging immunological drugs for chronic lymphocytic leukemia.Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma A panel of IgG1 b12 variants with selectively diminished or enhanced affinity for Fcγ receptors to define the role of effector functions in protection against HIV.Biological Characterization of a Stable Effector Functionless (SEFL) Monoclonal Antibody Scaffold in Vitro.Targeting B cells in treatment of autoimmunity.A novel liposomal formulation of FTY720 (fingolimod) for promising enhanced targeted delivery.Antigen Loss Variants: Catching Hold of Escaping Foes.Antibody-dependent cell-mediated cytotoxicity overcomes NK cell resistance in MLL-rearranged leukemia expressing inhibitory KIR ligands but not activating ligands.Chimeric, divalent and tetravalent anti-CD19 monoclonal antibodies with potent in vitro and in vivo antitumor activity against human B-cell lymphoma and pre-B acute lymphoblastic leukemia cell lines.Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers.Novel therapies for aggressive B-cell lymphoma The Fc-engineered CD19 antibody MOR208 (XmAb5574) induces natural killer cell-mediated lysis of acute lymphoblastic leukemia cells from pediatric and adult patients.

P2860

Q21131216-1607FE2B-1FC6-4F64-A831-AD6309DC07D6 Q21198858-92EA3711-79FD-4DBD-AB9F-D6D90DA086CA Q26775363-1A3084B7-472F-4660-B74D-2CE666F7F28D Q26828496-AC15D21D-EC9D-48EA-9C13-AE90F14A92CA Q27011836-170C39CA-52EB-458E-8FDA-3A17476A6D27 Q28079016-4274C400-20AB-4D04-87F7-87B7BFFD0A20 Q28265732-462A1E5F-2C82-49D1-A941-A2B44B64ADE5 Q28829762-8255F8C6-7187-4CC7-815F-0CCE154E5237 Q31104000-F93BEB31-FADE-4A98-88DA-110BA3B55952 Q33406478-C9D6AFEF-D3A0-4D6C-93D0-A02BA7DB669E Q33418091-DE4B42D2-2EB1-49E9-91D3-D87F9892A806 Q34440110-8D856F02-7A03-44DF-9F8D-318B4E727768 Q34488712-BF85DC59-8991-472F-AEE8-1B9BE1065105 Q34598149-58AD5F9C-B18C-45A3-9CFF-CEE10C4C195B Q34997715-DA6F2B8A-E745-497A-B0EB-1F7A84F7BEFD Q35307091-0FB8F9CC-A69F-49EE-9795-07388F1A8AE7 Q35599741-2BF15174-4A16-4892-A3FF-BD747D662D9B Q35861457-75DBA9F3-3128-494E-80CE-4FA0617F3391 Q36213288-9C4A015B-D95A-4161-A007-E93DECDA04A4 Q36311218-C7FE76B3-4243-4C92-B58A-8645EFE34A50 Q36870059-EFDF8153-5E59-440E-BF38-6D08D5720C46 Q36903955-73C5DCA9-4022-4CBA-A847-0975C47B291F Q36913118-07DF45DB-CFF4-43DE-8D08-652737C091BB Q37797475-F2EA44AD-7E0E-4905-B119-7B9BC4AF4850 Q38068494-7DB69555-E3D8-4B34-9CF0-342139C08D0A Q38124065-4A060699-2524-470E-A8F5-FA4619324DDA Q38334794-7656283B-1FF8-46E7-A5CC-B1C5A4037AB6 Q38366441-2F166FAD-0BB8-4BB8-9DC3-A113F6866688 Q38543771-D993482D-E644-4D06-96FB-B8FDED4F7FDF Q38551337-A9FA5C18-5C7E-4F76-B24B-5F05D8536034 Q38631835-05606885-925A-49B5-8831-ED381B069002 Q38725387-D6D3C90E-DDA8-4B0C-8A32-DED1D44D6377 Q38975656-0EB20E88-9FD7-4A81-ABCA-8B08FC2351FB Q39106527-9A3C9802-B665-4775-9F50-E2FBDBE1722F Q39175440-01F8EBA8-25CA-4A59-8782-0A677063E738 Q39270970-C2E64A6E-2B88-4596-A637-3A48F6A18173 Q39650162-EF49DDB8-7BA2-4803-B77E-91F8A928769D Q39654887-86CF1125-CA9E-4DD3-B05C-940B1DF19E58 Q42011578-7DC4F5AB-1A72-445C-93C0-17B47E5A8D8A Q44133396-41AE108D-85A5-4AA8-BD65-8171C12A1BA8

P2860

CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody.

http://www.wikidata.org/entity/Q33677456

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

CD19 targeting of chronic lymp ...... ngineered monoclonal antibody.

@ast

CD19 targeting of chronic lymp ...... ngineered monoclonal antibody.

@en

type

label

CD19 targeting of chronic lymp ...... ngineered monoclonal antibody.

@ast

CD19 targeting of chronic lymp ...... ngineered monoclonal antibody.

@en

prefLabel

CD19 targeting of chronic lymp ...... ngineered monoclonal antibody.

@ast

CD19 targeting of chronic lymp ...... ngineered monoclonal antibody.

@en

P1433

Q33677456-D13CCC80-D68E-44FC-8AC1-561652489FA6

P1476

Q33677456-A2BC7493-A12A-4123-A8A3-76F3095C96EF

P2093

Q33677456-1D01BF99-F832-41EA-B166-2EA2D1FFFE6D

Q33677456-45AFD9B3-1197-4270-AEFE-02086159FA99

Q33677456-6BABD87A-111D-4E34-930B-07F425832F7C

Q33677456-6FDB552B-A2EA-442E-BA04-A9FC6508E5AA

Q33677456-7DEAAA46-86A3-487C-9471-8E9962E968FC

Q33677456-815CBE4A-F73B-44A6-9D9D-B743C4900F3F

Q33677456-84155177-9D4F-40E5-8A51-36B86D9301DC

Q33677456-8D08E225-B916-431E-8721-AECE3B9267DD

Q33677456-90B6B5F2-169C-43E0-97F5-EC55B03E3ED0

Q33677456-B379DA38-9E34-4FC5-8246-028750E4B26B

P2860

Q33677456-0137DDE8-1379-4299-ACA0-C85136F0186F

Q33677456-01E2B79F-7C04-48CB-8576-15E034652E54

Q33677456-0905D4DE-EFC3-44F9-B79C-54DA8995B928

Q33677456-092AD9CF-324C-4700-AEB7-E940AD6801A3

Q33677456-114ACFB8-033D-4571-A6BD-8E140519DD61

Q33677456-12646ADF-C28A-4CB9-92CF-7C1FFB845A1D

Q33677456-1ED615AA-9C79-4B68-B7F2-21DB204E7CA8

Q33677456-25C8E2CF-3B5F-4D5B-B3E9-FC5D45954EB0

Q33677456-28501332-C9DB-4CC7-AD86-EBCFE444ADBE

Q33677456-4392FD1E-0405-44B2-8DEC-DD377942BFB5

P304

Q33677456-1A9C73A1-BC35-43E0-B7F1-01D8B11813F4

P31

Q33677456-31F7567E-5E78-4665-B8E0-B2F21B50A224

P356

Q33677456-9A455066-85BD-4806-800B-47526E4F16E3

P407

Q33677456-7E6DAC29-3422-4FDF-AE51-A7CB92253EBA

P433

Q33677456-A3A33EE5-A367-41A0-ABA2-DDD74E60817F

P478

Q33677456-ADEECD27-412D-4F4E-AEC8-5270A3ECD444

P50

Q33677456-4DD0AFB3-88D0-41D5-AE1B-942A771D34A1

Q33677456-63FE4E2A-629E-45D3-959B-0E8DB45AC829

P577

Q33677456-59018985-CF8B-4C29-879E-1567F2D4AA90

P5875

Q33677456-D9A8EDDA-59B1-420C-A9A0-9A24C72A40D6

P698

Q33677456-1B45529A-62DF-4E1F-AA36-8D6F07BA71DD

P921

Q33677456-07097F1E-8EE3-47E1-99BE-2599012102F4

Q33677456-6A1BBA1A-7EB1-458B-9FA4-0BAA10D471C5

Q33677456-F7C4AF3A-DF3B-45F5-90E5-9D24CAE45BE2

P932

Q33677456-5200DC1C-E4DE-47FB-990F-CEDBC648E474

P356

BLOOD-2009-06-229039

P1433

P1476

CD19 targeting of chronic lymp ...... ngineered monoclonal antibody.

@en

P2093

Amy Lehman

http://www.w3.org/2001/XMLSchema#string

Bo Yu

http://www.w3.org/2001/XMLSchema#string

Carolyn Cheney

http://www.w3.org/2001/XMLSchema#string

David Jarjoura

http://www.w3.org/2001/XMLSchema#string

Don M Benson

http://www.w3.org/2001/XMLSchema#string

Farrukh T Awan

http://www.w3.org/2001/XMLSchema#string

Jeffrey Jones

http://www.w3.org/2001/XMLSchema#string

John R Desjarlais

http://www.w3.org/2001/XMLSchema#string

Jonathan P Butchar

http://www.w3.org/2001/XMLSchema#string

Joseph Flynn

http://www.w3.org/2001/XMLSchema#string

P2860

Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical

Membrane IgM-induced tyrosine phosphorylation of CD19 requires a CD19 domain that mediates association with components of the B cell antigen receptor complex

Regulation of interferon-gamma during innate and adaptive immune responses

The molecular dissection of Fc gamma receptor mediated phagocytosis

MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment

Functions of natural killer cells

The CD19 signal transduction molecule is a response regulator of B-lymphocyte differentiation.

CD19 regulates intrinsic B lymphocyte signal transduction and activation through a novel mechanism of processive amplification.

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.

Engineered antibody Fc variants with enhanced effector function.

P304

1204-1213

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2009-06-229039

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

115

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-12-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40452613

http://www.w3.org/2001/XMLSchema#string

P698

19965644

http://www.w3.org/2001/XMLSchema#string

P921

P932

2826232

http://www.w3.org/2001/XMLSchema#string